BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 34350252)

  • 1. Osimertinib for the treatment of epidermal growth factor receptor-mutated non-small cell lung cancer patients with leptomeningeal metastases and different T790M status.
    Xu H; Chen H; Kong J; Zhang Y; Liu S; Yang G; Yang L; Wang Y
    Ann Transl Med; 2021 Jun; 9(11):937. PubMed ID: 34350252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Survival analysis of different kinds of tyrosine kinase inhibitors in the treatment of patients with epidermal growth factor receptor mutated non-small cell lung cancer and leptomeningeal metastasis].
    Xu HY; Chen HQ; Kong JX; Zhang Y; Liu S; Yang GJ; Wang Y
    Zhonghua Yi Xue Za Zhi; 2022 Feb; 102(6):399-405. PubMed ID: 35144338
    [No Abstract]   [Full Text] [Related]  

  • 3. A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy.
    Park S; Lee MH; Seong M; Kim ST; Kang JH; Cho BC; Lee KH; Cho EK; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Ann Oncol; 2020 Oct; 31(10):1397-1404. PubMed ID: 32634610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osimertinib combined with bevacizumab for leptomeningeal metastasis from EGFR-mutation non-small cell lung cancer: A phase II single-arm prospective clinical trial.
    Lu ZQ; Cai J; Wang X; Wei JP; Zeng ZM; Huang L; Liu AW
    Thorac Cancer; 2021 Jan; 12(2):172-180. PubMed ID: 33205587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Osimertinib Improves Overall Survival in Patients with Leptomeningeal Metastases Associated with
    Zhang M; Ma W; Liu H; Jiang Y; Qin L; Li W; Zhang J
    Evid Based Complement Alternat Med; 2021; 2021():6968194. PubMed ID: 34457028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real world efficacy of osimertinib in second line/beyond in patients with metastatic EGFR+ non-small cell lung cancer and role of paired tumour-plasma T790M testing at tyrosine kinase inhibitor resistance.
    Ma J; Tan SH; Yin DXC; Tran NTA; Tan GS; Lai GGY; Ang MK; Kanesvaran R; Jain A; Rajasekaran T; Tan EH; Lim TKH; Tan DS; Lim DW; Ng QS; Tan WL
    Transl Lung Cancer Res; 2023 Apr; 12(4):742-753. PubMed ID: 37197627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II Efficacy and Safety of 80 mg Osimertinib in Patients With Leptomeningeal Metastases Associated With Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer (BLOSSOM).
    Park S; Baldry R; Jung HA; Sun JM; Lee SH; Ahn JS; Kim YJ; Lee Y; Kim DW; Kim SW; Lee KH; Lee WJ; Choi JW; Chong K; Lee JI; Gwon SH; Son NH; Ahn MJ
    J Clin Oncol; 2024 Jun; ():JCO2400708. PubMed ID: 38828959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genotyping of Cerebrospinal Fluid Associated With Osimertinib Response and Resistance for Leptomeningeal Metastases in EGFR-Mutated NSCLC.
    Zheng MM; Li YS; Tu HY; Jiang BY; Yang JJ; Zhou Q; Xu CR; Yang XR; Wu YL
    J Thorac Oncol; 2021 Feb; 16(2):250-258. PubMed ID: 33122107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study.
    Yang JCH; Kim SW; Kim DW; Lee JS; Cho BC; Ahn JS; Lee DH; Kim TM; Goldman JW; Natale RB; Brown AP; Collins B; Chmielecki J; Vishwanathan K; Mendoza-Naranjo A; Ahn MJ
    J Clin Oncol; 2020 Feb; 38(6):538-547. PubMed ID: 31809241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osimertinib Improves Overall Survival in Patients With EGFR-Mutated NSCLC With Leptomeningeal Metastases Regardless of T790M Mutational Status.
    Lee J; Choi Y; Han J; Park S; Jung HA; Su JM; Lee SH; Ahn JS; Park K; Ahn MJ
    J Thorac Oncol; 2020 Nov; 15(11):1758-1766. PubMed ID: 32652216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular characteristics and prognostic factors of leptomeningeal metastasis in non-small cell lung cancer.
    Liu X; Li G; Zhang H; Chang Q; Fang M; Lu C; Tian P; Mei F
    Clin Neurol Neurosurg; 2023 Feb; 225():107572. PubMed ID: 36610238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjusted Indirect Comparison Using Propensity Score Matching of Osimertinib to Platinum-Based Doublet Chemotherapy in Patients with EGFRm T790M NSCLC Who Have Progressed after EGFR-TKI.
    Mann H; Andersohn F; Bodnar C; Mitsudomi T; Mok TSK; Yang JC; Hoyle C
    Clin Drug Investig; 2018 Apr; 38(4):319-331. PubMed ID: 29247383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osimertinib for Patients With Leptomeningeal Metastases Associated With EGFR T790M-Positive Advanced NSCLC: The AURA Leptomeningeal Metastases Analysis.
    Ahn MJ; Chiu CH; Cheng Y; Han JY; Goldberg SB; Greystoke A; Crawford J; Zhao Y; Huang X; Johnson M; Vishwanathan K; Yates JWT; Brown AP; Mendoza-Naranjo A; Mok T
    J Thorac Oncol; 2020 Apr; 15(4):637-648. PubMed ID: 31887431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidermal growth factor receptor-Mutated Non-small-cell Lung Cancer with Intracranial Progressions and Stable Extracranial Diseases Benefit from Osimertinib Regardless of T790M Mutational Status.
    Liao J; Huang Y; Gan J; Pang L; Ali WAS; Yang Y; Chen L; Zhang L; Fang W
    Cancer Control; 2022; 29():10732748221081360. PubMed ID: 35201951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osimertinib Combined with Systemic Chemotherapy for EGFR Mutant, T790M-Negative, Non-Small Cell Lung Cancer Patients Who Develop Leptomeningeal Metastases with Extracranial Progression to Prior EGFR TKI.
    Kim HR; Jo H; Kim H; Hong J; Park S; Jung HA; Lee SH; Ahn JS; Ahn MJ
    Cancer Res Treat; 2023 Jan; 55(1):344-349. PubMed ID: 35344648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase II Study of Osimertinib in Patients with Advanced-Stage Non-Small Cell Lung Cancer following Prior Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI) Therapy with EGFR and T790M Mutations Detected in Plasma Circulating Tumour DNA (PLASMA Study).
    Ang YLE; Zhao X; Reungwetwattana T; Cho BC; Liao BC; Yeung R; Loong HH; Kim DW; Yang JC; Lim SM; Ahn MJ; Lee SH; Suwatanapongched T; Kongchauy K; Ou Q; Yu R; Tai BC; Goh BC; Mok TSK; Soo RA
    Cancers (Basel); 2023 Oct; 15(20):. PubMed ID: 37894366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer with Leptomeningeal Metastases Pretreated with EGFR-Tyrosine Kinase Inhibitors.
    Saboundji K; Auliac JB; Pérol M; François G; Janicot H; Marcq M; Dubos-Arvis C; Renault A; Guisier F; Odier L; Gervais R; Chouaïd C
    Target Oncol; 2018 Aug; 13(4):501-507. PubMed ID: 30039345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical efficacy analysis of Osimertinib treatment for a patient with leptomeningeal metastasis of EGFR+ non-small cell lung cancer without the T790M mutation.
    Hu X; Chen W; Li X; Zhao C; Zhang C; Xiong F; Wu H
    Ann Palliat Med; 2019 Nov; 8(5):525-531. PubMed ID: 31865717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Osimertinib in EGFR-Mutated Advanced Non-small-Cell Lung Cancer With Different T790M Status Following Resistance to Prior EGFR-TKIs: A Systematic Review and Meta-analysis.
    Yi XF; Song J; Gao RL; Sun L; Wu ZX; Zhang SL; Huang LT; Ma JT; Han CB
    Front Oncol; 2022; 12():863666. PubMed ID: 35785185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment Response To Osimertinib In
    Li H; Yu T; Huang M; Guo A; Qian X; Yin Z
    Onco Targets Ther; 2019; 12():7785-7790. PubMed ID: 31571928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.